Onyx Pharmaceuticals (ONXX)
Q2 2012 Earnings Call
August 01, 2012 5:00 pm ET
N. Anthony Coles - Chief Executive Officer, President and Director
Helen Torley - Chief Commercial officer and Executive Vice President
Matthew K. Fust - Chief Financial Officer, Principal Accounting Officer and Executive Vice President
Michael G. King - Rodman & Renshaw, LLC, Research Division
Cory William Kasimov - JP Morgan Chase & Co, Research Division
Terence C. Flynn - Goldman Sachs Group Inc., Research Division
Rachel L. McMinn - BofA Merrill Lynch, Research Division
Howard Liang - Leerink Swann LLC, Research Division
Biren Amin - Jefferies & Company, Inc., Research Division
Matthew R. Wooten - Robert W. Baird & Co. Incorporated, Research Division
Navdeep Singh - Deutsche Bank AG, Research Division
Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division
Ling Wang - Summer Street Research Partners
Echo Yinghui He - Maxim Group LLC, Research Division
Ryan Martins - Lazard Capital Markets LLC, Research Division
Nicholas Bishop - Cowen and Company, LLC, Research Division
Ying Huang - Barclays Capital, Research Division
Marshall Urist - Morgan Stanley, Research Division
Jim Birchenough - BMO Capital Markets U.S.
Welcome to the Onyx Pharmaceuticals Conference Call. My name is Trish, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.
I would now like to turn the call over to Onyx Pharmaceuticals.
Thanks, Trish. Good afternoon. I'm Amy Figueroa, Senior Director of Investor Relations at Onyx Pharmaceuticals. Thank you for participating on our second quarter 2012 financial results conference call.